RT Journal Article
SR Electronic
T1 Longitudinal Influenza A Virus Screening of Retail Milk from Canadian Provinces (Rolling Updates)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.28.24308052
DO 10.1101/2024.05.28.24308052
A1 Wallace, Hannah L.
A1 Wight, Jordan
A1 Baz, Mariana
A1 Dowding, Barbara
A1 Flamand, Louis
A1 Hobman, Tom
A1 Jean, Francois
A1 Joy, Jeffrey B
A1 Lang, Andrew S.
A1 MacParland, Sonya
A1 McCormick, Craig
A1 Noyce, Ryan
A1 Russell, Rodney S.
A1 Sagan, Selena M.
A1 Rzeszutek, Gabriela J.
A1 Jafri, Mustafa S.
A1 Bogoch, Isaac
A1 Kindrachuk, Jason
A1 Rasmussen, Angela L.
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/06/04/2024.05.28.24308052.abstract
AB Highly pathogenic avian influenza (HPAI) H5N1 has caused the deaths of more than 100 million birds since 2021, and human cases since 1997 have been associated with significant morbidity and mortality. Given the recent detection of HPAI H5N1 in dairy cattle and H5N1 RNA detections in pasteurized retail milk in the United States, we established the Pan-Canadian Milk (PCM) Network. Through our network of collaborators from across Canada, retail milk is being procured longitudinally and sent to a central laboratory for testing for the presence of influenza A virus RNA. To date (3 June 2024), we have tested 34 retail milk samples from five Canadian provinces (NL, NS, PEI, NB, QC, MB, and AB) and all have tested negative for influenza A virus RNA. Testing is ongoing and these results will be updated on rolling basis as additional data becomes available. Despite no known HPAI infections of dairy cattle in Canada to date, H5N1 poses a significant threat to the health of both humans and other animals. Routine surveillance of retail milk on a national scale will allow for monitoring of infected dairy cattle on an ongoing basis in a cost-effective, standardized, scalable and easily accessible manner. Our network and testing will act as an early warning system which will enable rapid responses necessary to contain an outbreak should any samples test positive.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Canadian Institutes of Health Research (Tier 2 Canada Research Chair, grant number 950-231498 to JK) and by the Natural Sciences and Engineering Research Council Discovery Grant (RGPIN-2018-06036 to JK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors